Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
|Articles|May 1, 2012
- Pharmaceutical Executive-05-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - May 2012
Marooned at the Top
Advertisement
Articles in this issue
over 14 years ago
Pharma 50 Comment: Seeding Beyond the Baseover 14 years ago
Value-Based Pricing: Too High a Price for UK Pharma?over 14 years ago
Pharm Exec 50: Growth from the Bottom Upover 14 years ago
Country Report: South Africaover 14 years ago
Managing Information Overloadover 14 years ago
Super-Size Me: Optimizing the Information Explosionover 14 years ago
Government: Big Pharma's Best Friend in Emerging Markets?over 14 years ago
Information Overloadover 14 years ago
Pharma's Winning Innovative TechnologyAdvertisement
Related to this article
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Before You Sign with a New Hub Vendor, Ask These Four Questions
5